PhotoCure ASA (PHO.OL)
| Previous close | 56.50 |
| Open | 55.70 |
| Bid | 57.20 x 140900 |
| Ask | 57.50 x 97900 |
| Day's range | 55.70 - 57.60 |
| 52-week range | 40.70 - 71.90 |
| Volume | |
| Avg. volume | 81,909 |
| Market cap | 1.559B |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | 1,437.50 |
| EPS (TTM) | 0.04 |
| Earnings date | 15 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 23 May 2013 |
| 1y target est | 99.00 |
PR NewswireBladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the AUA 2024: the American Urological Association Annual Congress 2024 was held May 3-6, 2024, in San Antonio, TX, USA. The results of the BRAVO study performed within the VA healthcare system showed significant decreases in the risk of recurrence and progression, as well as the potential for improved overall survival in patients who received a blue light cystoscop
PR NewswirePhotocure ASA - Notice of the Annual General Meeting 23 May 2024
Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be held on 23 May 2024 at 17:00 hours (CEST), virtual through the general meeting portal administered by Euronext Securities Oslo (the "Euronext Securities Portal").
PR NewswirePhotocure ASA: Annual Report 2023
Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2023.
